肝癌组织中抗凝血酶Ⅲ基因表达的临床意义

doi:10.11904/j.issn.1002-3070.2018.02.005

实用肿瘤学杂志 ›› 2018, Vol. 32 ›› Issue (2): 117-121.doi: 10.11904/j.issn.1002-3070.2018.02.005

肝癌组织中抗凝血酶Ⅲ基因表达的临床意义

文娟娟, 瞿兵, 刘超

恩施土家族苗族自治州民族医院消化内科(恩施 445000)

收稿日期:2017-06-13 出版日期:2018-04-28 发布日期:2018-05-09
通讯作者: 文娟娟,E-mail:wjuanwhu@163.com
作者简介:文娟娟,女,(1983-),硕士,主治医师,从事消化系统疾病诊治的研究。

Clinical significance of antithrombin Ⅲ gene expression in hepatocellular carcinoma tissues

WEN Juanjuan, QU Bing, LIU Chao

Department of Gastroenterology,The Central Hospital of Enshi Autonomous Prefecture,Enshi 445000,China

Received:2017-06-13 Online:2018-04-28 Published:2018-05-09

摘要/Abstract

摘要： 目的探讨肝癌组织中抗凝血酶Ⅲ(Antithrombin-Ⅲ,AT3)基因表达水平及其与临床特征和预后的关系。方法收集公共数据库中214例肝癌组织的基因表达谱及相关临床数据,对样本中AT3基因表达水平与临床特征和预后的关系进行相关性分析。结果单因素分析提示,AT3低表达组中,血清甲胎蛋白含量较高(P＜0.001),肿瘤体积较大(P=0.015),TNM分期较差(P=0.001),转移风险较高(P＜0.001)。生存分析提示,肿瘤体积较大(P=0.023)、多发结节(P=0.047)、合并肝硬化(P=0.016)、TNM分期较晚(P＜0.001)、高转移风险(P=0.001)及AT3低表达(P=0.005)与肝癌患者预后有关。多因素Cox回归分析亦提示AT3表达水平是肝癌患者预后的独立影响因素(HR=0.850,95%CI:0.745~0.970,P=0.016)。结论肝癌组织中,AT3表达水平与患者临床特征及预后有关,其低表达可能是影响肝癌预后的危险因素之一。

关键词: 肝癌, 抗凝血酶III, 临床意义

Abstract: Objective The aim of this study was to investigate the expression of antithrombin Ⅲ(AT3)gene in hepatocellular carcinoma(HCC)and its relationship with clinical features and prognosis.Methods The profiles of gene expression and related clinical data of 214 HCC tissues were collected from the public database.Correlation analysis was conducted to investigate the association between the level of AT3 expression and clinical features,and the prognosis.Results Univariate analysis showed that with the low expression of AT3 in HCC tissues,there were a higher level of blood alpha fetoprotein(AFP)(P＜0.001),a larger tumor size(P=0.015),a poorer TNM stage(P=0.001),and a higher metastasis risk(P＜0.001).Survival analysis showed that tumor size was larger(P=0.023),multiple nodules(P=0.047),simultaneous cirrhosis(P=0.016),a poorer TNM stage(P＜0.001),a higher metastasis risk(P=0.001),and the lower expression of AT3(P=0.005).These were the risk factors of prognosis.Multivarate Cox analysis also showed a negative association between the expression of AT3 and the prognosis of HCC(HR=0.850,95%CI:0.745~0.970,P=0.016).Conclusion The expression of AT3 in HCC is associated with the clinical characteristics and prognosis of the patients.The low expression of AT3 is one of the risk factors for the prognosis of HCC.

Key words: Hepatocellular carcinoma, AT3 gene, Clinical significance

中图分类号:

R735.7

文娟娟, 瞿兵, 刘超. 肝癌组织中抗凝血酶Ⅲ基因表达的临床意义[J]. 实用肿瘤学杂志, 2018, 32(2): 117-121.

WEN Juanjuan, QU Bing, LIU Chao. Clinical significance of antithrombin Ⅲ gene expression in hepatocellular carcinoma tissues[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 117-121.

参考文献

1 王黎君,殷鹏,刘韫宁,等.1990年与2013年中国人群肝癌疾病负担研究[J].中华流行病学杂志,2016,37(6):758-762.
2 Torre LA,Siegel RL,Ward EM,et al.Global cancer incidence and mortality rates and trends—An update [J].Cancer Epidemiol Biomarkers Prev,2016,25(1):16-27.
3 钱程,杨智.肝癌基因治疗的基础研究与临床应用[J].分子诊断与治疗杂志,2010,2(3):145-148.
4 Iwako H,Tashiro H,Amano H,et al.Prognostic significance of antithrombin III levels for outcomes in patients with hepatocellular carcinoma after curative hepatectomy [J].Ann Surg Oncol,2012,19(9):2888-2896.
5 Kuroda S,Tashiro H,Kobayashi T,et al.Administration of antithrombin III attenuates posthepatectomy liver failure in hepatocellular carcinoma [J].Dig Surg,2015,32(3):173-180.
6 Roessler S,Jia HL,Budhu A,et al.A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients [J].Cancer Res,2010,70(24):10202-10212.
7 Asmal M,Seaman M,Lin W,et al.Inhibition of HCV by the serpin antithrombin III [J].Virol J,2012,9:226.
8 Mizuguchi T,Kawamoto M,Meguro M,et al.Serum antithrombin III level is well correlated with multiple indicators for assessment of liver function and diagnostic accuracy for predicting postoperative liver failure in hepatocellular carcinoma patients [J].Hepatogastroenterology,2012,59(114):551-557.
9 Buller HR,Boon TA,Henny CP,et al.Estrogen-induced deficiency and decrease in antithrombin III activity in patients with prostatic cancer [J].J Urol,1982,128(1):72-74.
10 Honegger H,Anderson N,Hewitt LA,et al.Antithrombin III profiles in malignancy,relationship primary tumors and metastatic sites [J].Thromb Haemost,1981,46(2):500-503.
11 Kurata M,Okajima K,Kawamoto T,et al.Antithrombin reduces reperfusion-induced hepatic metastasis of colon cancer cells [J].World J Gastroenterol,2006,12(1):60-65.
12 Meyer-Siegler KL,Cox J,Leng L,et al.Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum:Complex formation as a mechanism of inactivation [J].Cancer Lett,2010,290(1):49-57.
13 Shirai Y,Uwagawa T,Shiba H,et al.Recombinant thrombomodulin suppresses tumor growth of pancreatic cancer by blocking thrombin-induced PAR1 and NF-κB activation [J].Surgery,2017,161(6):1675-1682.
14 Kaufmann R,Rahn S,Pollrich K,et al.Thrombin-mediated hepatocellular carcinoma cell migration:cooperative action via proteinase-activated receptors 1 and 4 [J].J Cell Physiol,2007,211(3):699-707.
15 Grbˇci＇c P,Tomljanovi＇c I,Klobuˇcar M,et al.Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling [J].Biochem Biophys Res Commun,2017,487(4):782-788.
16 Yamaguchi Y,Shao Z,Sharif S,et al.Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage [J].J Biol Chem,2013,288(5):3097-3111.

[1]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[2]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[3]	徐兵, 黄素钦, 吴林岚, 魏建威, 杨晓梅, 赵芝萍, 陈怡, 蒋晓织. 异体淋巴细胞和自体淋巴细胞序贯局部注射对小鼠肝癌移植瘤的治疗作用[J]. 实用肿瘤学杂志, 2018, 32(6): 493-497.
[4]	贺伟, 母齐鸣, 王刚, 万波, 廖波, 杨娟. TACC3和p53蛋白在原发性肝癌组织中的表达及其临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 420-425.
[5]	石小康(综述), 丁佑铭(审校). 螺杆菌属与原发性肝癌关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(3): 271-274.
[6]	王睿,余陈欢,方杰. miR-409-5p对肝癌细胞系HepG2增殖及迁移的影响[J]. 实用肿瘤学杂志, 2017, 31(4): 305-309.
[7]	周春芳，赵珊珊，孙泽群，吴军，查火龙，袁雅红. 酸性环境诱导肝癌HepG2细胞EMT[J]. 实用肿瘤学杂志, 2017, 31(3): 199-204.
[8]	张丽霞，潘双花，何英平. 原发性肝癌患者心电图与转氨酶和电解质的相关性研究[J]. 实用肿瘤学杂志, 2016, 30(6): 523-526.
[9]	杨晓文, 于爱清, 杨毅. Nanog调控细胞周期相关蛋白影响HepG2细胞增殖能力[J]. 实用肿瘤学杂志, 2016, 30(5): 425-429.
[10]	赵相轩, 温锋, 毛晓楠综述, 卢再鸣审校. 细胞凋亡在原发性肝癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2016, 30(5): 448-452.
[11]	余庆, 张文美, 孙迎迎, 龚媛媛, 李东升, 王小莉. TRIM5α对肝癌细胞增殖和凋亡的影响[J]. 实用肿瘤学杂志, 2016, 30(2): 103-108.
[12]	康振国, 纪卫政, 顾俊鹏, 朱帝文, 张海潇, 任伟新. 肝癌射频消融术后联合替吉奥节拍化疗的疗效评价[J]. 实用肿瘤学杂志, 2016, 30(1): 17-22.
[13]	李凯, 杨光, 沈海洋, 刘家. 巨块型肝癌患者首次TACE后发热的临床意义及影响因素[J]. 实用肿瘤学杂志, 2015, 29(6): 528-532.
[14]	尹立楠, 刘岩. 微波消融治疗肝癌187例的临床疗效评价研究[J]. 实用肿瘤学杂志, 2015, 29(5): 395-399.
[15]	曲文书,华海清. 原发性肝癌骨转移55例预后分析[J]. 实用肿瘤学杂志, 2015, 29(4): 327-332.

肝癌组织中抗凝血酶Ⅲ基因表达的临床意义

Clinical significance of antithrombin Ⅲ gene expression in hepatocellular carcinoma tissues

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价